| Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers R Katayama, AT Shaw, TM Khan, M Mino-Kenudson, BJ Solomon, ... Science translational medicine 4 (120), 120ra17-120ra17, 2012 | 1466 | 2012 |
| The complex role of tumor-infiltrating macrophages A Christofides, L Strauss, A Yeo, C Cao, A Charest, VA Boussiotis Nature immunology 23 (8), 1148-1156, 2022 | 288 | 2022 |
| mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1 AC Faber, EM Coffee, C Costa, A Dastur, H Ebi, AN Hata, AT Yeo, ... Cancer discovery 4 (1), 42-52, 2014 | 142 | 2014 |
| Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer AC Faber, AF Farago, C Costa, A Dastur, M Gomez-Caraballo, R Robbins, ... Proceedings of the National Academy of Sciences 112 (11), E1288-E1296, 2015 | 136 | 2015 |
| Single-cell RNA sequencing reveals evolution of immune landscape during glioblastoma progression AT Yeo, S Rawal, B Delcuze, A Christofides, A Atayde, L Strauss, L Balaj, ... Nature immunology 23 (6), 971-984, 2022 | 106 | 2022 |
| Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancers AN Hata, A Yeo, AC Faber, E Lifshits, Z Chen, KA Cheng, Z Walton, ... Cancer research 74 (11), 3146-3156, 2014 | 99 | 2014 |
| A PDGFRα-driven mouse model of glioblastoma reveals a stathmin1-mediated mechanism of sensitivity to vinblastine HJ Jun, VA Appleman, HJ Wu, CM Rose, JJ Pineda, AT Yeo, B Delcuze, ... Nature communications 9 (1), 3116, 2018 | 39 | 2018 |
| Immune checkpoint blockade biology in mouse models of glioblastoma AT Yeo, A Charest Journal of cellular biochemistry 118 (9), 2516-2527, 2017 | 24 | 2017 |
| Bcl-XL, but not Bcl-2, can protect human B-lymphoma cell lines from parthenolide-induced apoptosis AT Yeo, JA Porco Jr, TD Gilmore Cancer letters 318 (1), 53-60, 2012 | 24 | 2012 |
| Disulfide-mediated stabilization of the IκB kinase binding domain of NF-κB essential modulator (NEMO) L Zhou, AT Yeo, C Ballarano, U Weber, KN Allen, TD Gilmore, A Whitty Biochemistry 53 (50), 7929-7944, 2014 | 18 | 2014 |
| EGFRvIII tumorigenicity requires PDGFRA co-signaling and reveals therapeutic vulnerabilities in glioblastoma AT Yeo, HJ Jun, VA Appleman, P Zhang, H Varma, JN Sarkaria, ... Oncogene 40 (15), 2682-2696, 2021 | 12 | 2021 |
| CRISPR/Cas9-based editing of a sensitive transcriptional regulatory element to achieve cell type-specific knockdown of the NEMO scaffold protein M Babaei, Y Liu, SM Wuerzberger-Davis, EZ McCaslin, CJ DiRusso, ... PLoS One 14 (9), e0222588, 2019 | 11 | 2019 |
| Driver mutations dictate the immunologic landscape and response to checkpoint immunotherapy of glioblastoma AT Yeo, R Shah, K Aliazis, R Pal, T Xu, P Zhang, S Rawal, CM Rose, ... Cancer immunology research 11 (5), 629-645, 2023 | 7 | 2023 |
| Adaptive Significance of ERα Splice Variants in Killifish (Fundulus heteroclitus) Resident in an Estrogenic Environment KA Cotter, D Nacci, D Champlin, AT Yeo, TD Gilmore, GV Callard Endocrinology 157 (6), 2294-2308, 2016 | 7 | 2016 |
| A high-grade glioma with SOS1 amplification B Vidal, C Bryke, N Hsu, R Alterman, AT Yeo, A Charest, H Varma Clinical Neuropathology 39 (3), 126, 2020 | 3 | 2020 |
| Inhibition of oncogenic transcription factor REL by the natural product derivative calafianin monomer 101 induces proliferation arrest and apoptosis in human B-lymphoma cell lines AT Yeo, S Chennamadhavuni, A Whitty, JA Porco Jr, TD Gilmore Molecules 20 (5), 7474-7494, 2015 | 2 | 2015 |
| Evolution of glioblastoma immune landscape during initiation and progression as revealed by single-cell RNA sequencing A Charest, A Yeo, B Delcuze Brain Tumor Research and Treatment 10 (Suppl), 2022 | | 2022 |
| Abstract B15: Tumor genotype dependency of checkpoint blockade therapy in EGFR-driven glioblastoma AT Yeo, A Charest Cancer Immunology Research 8 (3_Supplement), B15-B15, 2020 | | 2020 |
| Tumor genotype dependency of checkpoint blockade therapy in EGFR-driven glioblastoma. AT Yeo, A Charest CANCER IMMUNOLOGY RESEARCH 8 (3), 93-93, 2020 | | 2020 |
| Tumor genotypes of EGFR-driven glioblastoma dictate diverse immune landscapes which confers selective responses to checkpoint blockade immunotherapy A Yeo Tufts University-Graduate School of Biomedical Sciences, 2020 | | 2020 |
